News | April 02, 2012

HORIZONS II AMI Trial Examines Promus Element Verses Omega Stent

April 2, 2012 — Boston Scientific announced its support of the HORIZONS II AMI clinical trial, which is designed to evaluate the safety and efficacy of the Promus Element Plus everolimus-eluting platinum chromium (PtCr) coronary stent compared to the Omega platinum chromium bare-metal stent in patients experiencing an acute myocardial infarction (AMI). The trial is co-funded by Boston Scientific and The Medicines Company, and the Cardiovascular Research Foundation (CRF) will act as academic research organization (ARO). An overview of the trial design was presented at the American College of Cardiology’s 61st Annual Scientific Session by Gregg W. Stone, M.D., professor of medicine and director of research and education at the Center for Interventional Vascular Therapy at Columbia University Medical Center/New York-Presbyterian Hospital, and global principal investigator of the trial.

HORIZONS II AMI is a randomized, double-blind, superiority clinical trial that plans to enroll 7,000 to 10,000 patients at up to 400 sites worldwide, making it the largest randomized trial to study coronary stents in heart attack patients. The trial will compare the Promus Element stent to the Omega stent in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation acute myocardial infarction (STEMI). All patients will be pre-treated with bivalirudin, aspirin and prasugrel, and then randomized to clopidogrel or prasugrel at 30 days post-procedure. The two primary clinical endpoints are target lesion revascularization (TLR) and stent thrombosis at 12 months. The study is designed to have sufficient power to demonstrate superiority for both endpoints. Clinical follow-up will occur at 30 days, six months and every 12 months out to three years. The non-inferiority pharmacology endpoint is death, MI, stroke, stent thrombosis or TIMI (thrombolysis in myocardial infarction) major/minor bleeding between one and 15 months. Patient enrollment in the trial is scheduled to begin late 2012. Data from the trial is expected to be used to support an expanded indication for the Promus Element stent for the treatment of STEMI patients.

"Heart attack patients are frequently treated with bare-metal stents, and remain at high risk for death and stent thrombosis despite successful percutaneous coronary angioplasty," said Stone. "As the largest primary PCI randomized trial ever performed in heart attack patients, HORIZONS II AMI is expected to provide essential guidance for physicians as to which stents and drugs will optimize outcomes following a heart attack."

The HORIZONS II AMI trial builds on results from the original HORIZONS AMI trial, which evaluated 3,006 patients randomized to receive either drug-eluting stents or bare-metal stents for the treatment of AMI. Data from that global trial were used to support U.S. Food and Drug Administration approval for an expanded indication to treat AMI patients with the Ion paclitaxel-eluting platinum chromium coronary stent system and the Taxus Liberte paclitaxel-eluting coronary stent system, which was received in February 2012. These devices are currently the only drug-eluting stent systems in the United States with an approved indication to treat patients with AMI.

"Boston Scientific continues to support large clinical trials that provide the medical community with data that can be used in combination with broader clinical judgment to develop optimal treatment strategies for challenging patient and lesion subsets," said Keith D. Dawkins, M.D., global chief medical officer for Boston Scientific. "We look forward to the results of this trial comparing the latest generation of drug-eluting and bare-metal stents on the advanced PtCr Element platform."

The safety and effectiveness of the Promus Element Plus stent system have not been established in patients with AMI. The Omega bare-metal stent system is an investigational device in the United States and is not available for sale.

For more information:

Related Content

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Overlay Init